American Journal of Epidemiology Advance Access originally published online on July 26, 2007
American Journal of Epidemiology 2007 166(8):894-901; doi:10.1093/aje/kwm157
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIGINAL CONTRIBUTIONS |
Association of Oral Contraceptive Use, Other Contraceptive Methods, and Infertility with Ovarian Cancer Risk
1 Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
2 Department of Epidemiology, Harvard School of Public Health, Boston, MA
3 Department of Medicine, Maine Medical Center, Portland, ME
4 Department of Surgery and Alvin J. Siteman Cancer Center, Washington University School of Medicine and Barnes Jewish Hospital, St. Louis, MO
5 Department of Biostatistics, Harvard School of Public Health, Boston, MA
Correspondence to Dr. Shelley S. Tworoger, Channing Laboratory, 181 Longwood Avenue, 3rd Floor, Boston, MA 02115 (e-mail: nhsst{at}channing.harvard.edu).
Received for publication December 13, 2006. Accepted for publication April 23, 2007.
Although oral contraceptives are protective for ovarian cancer, it is unclear how long this protection persists. The authors prospectively assessed this question as well as associations of other, less studied contraceptive methods (tubal ligation, rhythm method, diaphragm, condoms, intrauterine device, foam, spousal vasectomy) and infertility with ovarian cancer risk among 107,900 participants in the US Nurses' Health Study. During 28 years of follow-up (1976–2004), 612 cases of invasive epithelial ovarian cancer were confirmed. Duration of oral contraceptive use was inversely associated with risk (p-trend = 0.02), but no clear trend was observed for years since last use. However, for women using oral contraceptives for >5 years, the rate ratio for ovarian cancer for 
20 years since last use was 0.58 (95% confidence interval (CI): 0.39, 0.87), with no association found for >20 years since last use (rate ratio (RR) = 0.92, 95% CI: 0.61, 1.39). Tubal ligation (RR = 0.66, 95% CI: 0.50, 0.87) was associated with decreased ovarian cancer risk, whereas intrauterine device use (RR = 1.76, 95% CI: 1.08, 2.85) and infertility (RR = 1.36, 95% CI: 1.07, 1.75) were associated with an increased risk. Results suggest that the beneficial effect of oral contraceptives on ovarian cancer risk attenuates after 20 years since last use. Furthermore, tubal ligation, intrauterine device use, and infertility were associated with ovarian cancer risk.
contraception; contraceptives, oral; infertility; ovarian neoplasms
Abbreviations: CI, confidence interval; IUD, intrauterine device; RR, rate ratio
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Effects of Oral Contraceptives or a Gonadotropin-Releasing Hormone Agonist on Ovarian Carcinogenesis in Genetically Engineered Mice Cancer Prevention Research, September 1, 2009; 2(9): 792 - 799.
|
|
|
|
 |
|
 J. L. Hecht, J. Kotsopoulos, S. E. Hankinson, and S. S. Tworoger Relationship between Epidemiologic Risk Factors and Hormone Receptor Expression in Ovarian Cancer: Results from the Nurses' Health Study Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1624 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Rosenberg, Y. Zhang, P. F. Coogan, B. L. Strom, and J. R. Palmer A Case-Control Study of Oral Contraceptive Use and Incident Breast Cancer Am. J. Epidemiol., February 15, 2009; 169(4): 473 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jensen, H. Sharif, J. H. Olsen, and S. K. Kjaer Risk of Breast Cancer and Gynecologic Cancers in a Large Population of Nearly 50,000 Infertile Danish Women Am. J. Epidemiol., July 1, 2008; 168(1): 49 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Moorman, B. Calingaert, R. T. Palmieri, E. S. Iversen, R. C. Bentley, S. Halabi, A. Berchuck, and J. M. Schildkraut Hormonal Risk Factors for Ovarian Cancer in Premenopausal and Postmenopausal Women Am. J. Epidemiol., May 1, 2008; 167(9): 1059 - 1069. [Abstract] [Full Text] [PDF]
|
|